AliquantumRX, Inc.

AliquantumRx is a clinical-stage pharmaceutical company developing Cethromycin HCl, a short-course therapy designed to eliminate liver-stage malaria relapse and prevent recurrent malaria infections. The company is advancing its lead candidate through human clinical trials with a strategy aimed at achieving proof-of-concept and obtaining a Priority Review Voucher for regulatory and commercial benefits.